FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported) January 5, 2006

 

 

REPLIGEN CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

 

DELAWARE

(State or Other Jurisdiction of Incorporation)

 

0-14656   04-2729386
(Commission File Number)   (IRS Employer Identification No.)

 

41 Seyon Street, Building #1, Suite 100, Waltham, Massachusetts   02453
(Address of Principal Executive Offices)   (Zip Code)

 

(781) 250-0111

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 7.01 Regulation FD Disclosure.

 

On January 6, 2005, Repligen announced in a press release that on January 5, 2006, Repligen Corporation and The University of Michigan have jointly filed a complaint against Bristol-Myers Squibb Corporation (BMS) in the United States District Court for the Eastern District of Texas for infringement of U.S. Patent No. 6,685,941 in connection with BMS’ Orencia®. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

2

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Date: January 6, 2006

  

REPLIGEN CORPORATION

 

By:  /s/  Walter C. Herlihy                

Walter C. Herlihy

Chief Executive Officer and President

 

3

EXHIBIT INDEX

 

Exhibit No.
   

Description

99.1    Repligen Corporation Press Release dated January 6, 2006